Why Vascular Solutions Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Vascular Solutions has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Vascular and see what CAPS investors are saying about the stock right now.
Minneapolis, Minn. (1996)
Health care supplies
Co-Founder/CEO Howard Root
Return on Equity (average, past 3 years)
Cash / Debt
$19.7 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
Just yesterday, CAPS member rknapton succinctly summed up the Vascular outperform case for our community: "Long. Medical instruments company. Nice steady growth. Buying back stock. Cash flow from operating activities growing. Earnings grew 17% on a 9% boost in revenues last quarter. Not bad here at 21x fwd estimates."
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Vascular may not be your top choice.
Your financial health is just as important as your personal health. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.
The article Why Vascular Solutions Is Poised to Outperform originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.